bpc-157 clinical trials 2024 Explained: Benefits, Safety & Oral vs Injectable Options BPC-157 FDA Approval Status: Is
Description
However, around 85% of PA patients have parietal cell antibodies, which means they are a sensitive marker for the disease
Reference: Cox, H., Miller, G., & Eichner, D
Complete verification, from raw actives to finished product
Plemel JR, Stratton JA, Michaels NJ, Rawji KS, Zhang E, Sinha S, Baaklini CS, Dong Y, Ho M, Thorburn K, et al
